8-K/A
filed March 8, 2024, 6:59 PM ET
CIK 0001506928
other material
confidence high
sentiment positive
materiality 0.80
Avinger enters strategic partnership with Zylox-Tonbridge; receives $7.5M initial investment
Avinger Inc
- License Agreement for Avinger products in Greater China; 20-year initial term, mid-single to high-single digit royalty.
- Collaboration Agreement gives Avinger option to distribute Zylox-Tonbridge peripheral products in U.S. and Germany.
- Purchaser invested $7.5M for common shares and Series F preferred; potential $7.5M more on Milestones (FDA registration, $10M revenue).
- Jonathon Zhong Zhao appointed to Board as Class II director.
- Loan Amendment with CRG extends interest-only period to Dec 2026; interest may be paid in kind.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jonathon Zhong Zhao was appointed as Class II Director at Avinger Inc.
- Action
- appointed
- Role
- Class II Director
Exact text from the filing
Jonathon Zhong Zhao was appointed to serve as a Class II member of the Board.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Avinger Inc: Filed amendment to Series E Convertible Preferred Stock certificate reducing beneficial ownership limitation (effective 2024-03-04).
- Change
- charter amendment
- Effective
- 2024-03-04
Exact text from the filing
on March 4, 2024, the Company filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (the “Series E Amendment”).
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Avinger Inc: Filed Certificate of Designation of Series F Preferred Stock (effective 2024-03-04).
- Change
- charter amendment
- Effective
- 2024-03-04
Exact text from the filing
on March 4, 2024, the Company filed the Series F Certificate of Designation, designating 7,224 shares of Series F Preferred Stock.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Avinger Inc: Filed Certificate of Designation of Series A-1 Preferred Stock (effective 2024-03-04).
- Change
- charter amendment
- Effective
- 2024-03-04
Exact text from the filing
on March 4, 2024, the Company filed the Series A-1 Certificate of Designation, designating shares of Series A-1 Preferred Stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Avinger Inc entered into Securities Purchase Agreement with Zylox-Tonbridge Medical Limited valued at $15 million (effective 2024-03-04).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Zylox-Tonbridge Medical Limited
- Value
- $15 million
- Effective
- 2024-03-04
Exact text from the filing
the Company and Zylox-Tonbridge Medical Limited, a wholly-owned subsidiary of Zylox-Tonbridge (the “Purchaser”), entered into a Securities Purchase Agreement (the “Purchase Agreement”), pursuant to which the Purchaser agreed to purchase, in two tranches, up to an aggregate of $15 million in shares of the Company’s common stock
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Avinger Inc entered into License and Distribution Agreement with Zylox-Tonbridge Medical Technology Co., Ltd. (effective 2024-03-04).
- Action
- entry
- Agreement
- license
- Counterparty
- Zylox-Tonbridge Medical Technology Co., Ltd.
- Effective
- 2024-03-04
Exact text from the filing
On March 4, 2024, Avinger, Inc. (“Avinger” or the “Company”) entered into a License and Distribution Agreement (the “License Agreement”) with Zylox-Tonbridge Medical Technology Co., Ltd. (“Zylox-Tonbridge”) effective as of the Initial Closing (defined below)
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Avinger Inc entered into Strategic Cooperation and Framework Agreement with Zylox-Tonbridge Medical Technology Co., Ltd. (effective 2024-03-04).
- Action
- entry
- Agreement
- collaboration
- Counterparty
- Zylox-Tonbridge Medical Technology Co., Ltd.
- Effective
- 2024-03-04
Exact text from the filing
on March 4, 2024, the Company and Zylox-Tonbridge also entered into a Strategic Cooperation and Framework Agreement in conjunction with the Initial Closing (the “Collaboration Agreement”
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.4
Avinger Inc shareholders approved Approval of License Agreement, Purchase Agreement, and related transactions at the 2024-03-04 meeting.
- Outcome
- passed
- Meeting
- 2024-03-04
Exact text from the filing
On March 4, 2024, the holders of all of the outstanding shares of the Series A Preferred Stock and Series E Preferred Stock approved the License Agreement, the Purchase Agreement, and the transactions contemplated thereby, including the amendment, the issuance of the Series F Preferred Stock and Series G Preferred stock, the Exchange, and the Series E Amendment, by written consent.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.